よむ、つかう、まなぶ。
会議資料 (297 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00044.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第66回 12／12）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
要望番号；IV-144
report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417–28.
16) Saraceni F, et al.Thiotepa-busulfan-fludarabine compared to busulfan- fludarabine for sibling
and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget.
2018;9(3):3379–93.
17) Craddock C, et al. Augmented reduced-intensity regimen does not improve postallogeneic
transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2020;39:768–78.
18) Schmid C, et al. Sequential regimen of chemotherapy, reducedintensity conditioning for
allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk
acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675–87.
19) Brissot E et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced
intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or
10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter,
phase 2 trial. Blood Cancer J. 2024;14:31.
20) Kim H et al. A randomized comparison of cyclophosphamide vs. reduced dose
cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients
with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol. 2012;91:145969.
21) Patriarca F et al. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II
Multicenter Randomized Study from the GITMO Group. Biol Blood Marrow Transplant.
2019;25:932-40.
22) Mohty M et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic
stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study
from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439-43.
23) Mei M et al. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with
Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host
Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biol Blood Marrow
Transplant. 2020;26:1425-32.
24) Spyridonidis A et al. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for
Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the
Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7:e812.
25) Srinivasan R et al. Overcoming graft rejection in heavily transfused and allo-immunised
patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell
transplantation. Br J Haematol. 2006;133:305-14.
26) Maury S et al. Improved outcome of patients older than 30 years receiving HLA-identical
sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using
fludarabine-based conditioning: a comparison with conventional conditioning regimen.
Haematologica. 2009;94:1312-5.
55
297 / 451
report of the chronic malignancies working party of the EBMT. Br J Haematol. 2021;195:417–28.
16) Saraceni F, et al.Thiotepa-busulfan-fludarabine compared to busulfan- fludarabine for sibling
and unrelated donor transplant in acute myeloid leukemia in first remission. Oncotarget.
2018;9(3):3379–93.
17) Craddock C, et al. Augmented reduced-intensity regimen does not improve postallogeneic
transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2020;39:768–78.
18) Schmid C, et al. Sequential regimen of chemotherapy, reducedintensity conditioning for
allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk
acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675–87.
19) Brissot E et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced
intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or
10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter,
phase 2 trial. Blood Cancer J. 2024;14:31.
20) Kim H et al. A randomized comparison of cyclophosphamide vs. reduced dose
cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients
with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol. 2012;91:145969.
21) Patriarca F et al. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II
Multicenter Randomized Study from the GITMO Group. Biol Blood Marrow Transplant.
2019;25:932-40.
22) Mohty M et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic
stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study
from the European Group for Blood and Marrow Transplantation. Blood. 2010;116:4439-43.
23) Mei M et al. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with
Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host
Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biol Blood Marrow
Transplant. 2020;26:1425-32.
24) Spyridonidis A et al. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for
Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the
Acute Leukemia Working Party of the EBMT. Hemasphere. 2023;7:e812.
25) Srinivasan R et al. Overcoming graft rejection in heavily transfused and allo-immunised
patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell
transplantation. Br J Haematol. 2006;133:305-14.
26) Maury S et al. Improved outcome of patients older than 30 years receiving HLA-identical
sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using
fludarabine-based conditioning: a comparison with conventional conditioning regimen.
Haematologica. 2009;94:1312-5.
55
297 / 451